Aflac Cancer — Foreign currency translation and other decreased by 163.9% to -$62.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 138.8%, from $160.00M to -$62.00M.
Large fluctuations indicate high exposure to foreign currency risk, which can obscure underlying operational performance.
Captures the impact of fluctuations in exchange rates on the valuation of assets and liabilities within the cancer segme...
Common for multinational insurers; peers with significant Japanese or international exposure report similar translation impacts.
afl_segment_cancer_foreign_currency_translation_and_other| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$133.00M | -$133.00M | -$133.00M | -$133.00M | -$19.00M | -$243.00M | -$90.00M | -$189.00M | -$169.00M | -$297.00M | $160.00M | $97.00M | -$62.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +85.7% | <-999% | +63.0% | -110.0% | +10.6% | -75.7% | +153.9% | -39.4% | -163.9% |
| YoY Change | — | — | — | — | +85.7% | -82.7% | +32.3% | -894.7% | +30.5% | — | +184.7% | +157.4% | -138.8% |